Sponsored by:
Hewlett Packard (HPQ)
Dell (DELL)
Facebook (FB)
Apple (AAPL)
Focus Stocks
Featured Stories
Fred's First Quarter 2012 EPS Increase 17%
Newell Rubbermaid to Reaffirm Fiscal Year 2012 Outlook
Best ETFs For Facebook Exposure
McDonald's Announces Quarterly Cash Dividend
Is KB HOME Closing in to Resistance?
Research Analyst's New Ratings ( AKS, RKT, ONXX, GILD, CELG, BIIB, BEAV, AVEO, AMGN, IDIX )
Published on Friday, 10 February 2012 08:55 Written by Danny Miller
New York, February 10th (TradersHuddle.com) - These are the research analyst new ratings before the market open.
AK Steel (NYSE:AKS) was downgraded to a Neutral from Buy at Citigroup.
Rock-Tenn (NYSE:RKT) was initiated with a Buy at Citigroup.
Onyx Pharmaceuticals (NASDAQ:ONXX) was initiated with Underweight at Morgan Stanley.
Gilead Sciences (NASDAQ:GILD) was initiated with Overweight at Morgan Stanley.
Celgene (NASDAQ:CELG) was initiated with Overweight at Morgan Stanley.
Biogen Idec (NASDAQ:BIIB) was initiated with Overweight at Morgan Stanley.
BE Aerospace (NASDAQ:BEAV) was initiated with Equal Weight at Morgan Stanley.
AVEO Pharmaceuticals (NASDAQ:AVEO) was initiated with Equal Weight at Morgan Stanley.
Amgen (NASDAQ:AMGN) was initiated with Equal Weight at Morgan Stanley.
Idenix Pharmaceuticals (NASDAQ:IDIX) was initiated with Equal Weight at Barclays.
Related Articles
- New Analyst Coverage
- Neutral Short Term Pattern on Rock-Tenn
- Gilead Files European Marketing Application for Boosting Agent Cobicistat
- RockTenn and Peoples Gas Break Ground for Natural Gas in Fernandina Beach
- Is Rock-Tenn Close to Support?
- Celgene Corporation to Present at Sanford C. Bernstein’s 28th Annual Strategic Decisions Conference
- RockTenn to Present at the Goldman Sachs Basic Materials Conference
- Gilead Is Close to Resistance
- Trading Idea: Is AK Steel Breaking Down?
- AK Steel is Near a Key Support Area
Related Partner Headlines
- New Drug Application for Regorafenib for the Treatment of Metastatic Colorectal Cancer Submitted by Bayer - Benzinga
- From Earlier: Phase 3 MISSION trial of Nexavar in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival - Benzinga
- Gilead Sciences Inc (GILD): Today's Featured Drugs Winner - TheStreet.com
- J.P. Morgan Reiterates Overweight Rating, $65 PT for Gilead Sciences - Benzinga
- UPDATE: FDA Advisory Committee Supports Approval of Gilead's Once-Daily Quad Single Tablet Regimen for HIV - Benzinga
- From Earlier: FDA Advisory Committee Supports Approval of Gilead's Truvada® for Reducing the Risk of Acquiring HIV - Benzinga
- AK Steel Holding Stock To Go Ex-dividend Tomorrow (AKS) - TheStreet.com
- The Day Ahead: Valuation-Off - TheStreet.com
- Ex-Dividend Stocks: DuPont, AK Steel - TheStreet.com
- AK Steel Announces Price Increase For Carbon Steel Products - Benzinga
JIM CRAMER wants to work for YOU. JIM does the research -- YOU get email alerts each time he trades. JIM provides access to his actual portfolio -- YOU can use it to guide your portfolio strategy.
Try Jim's Action Alerts PLUS for FREE!
TradersHuddle Search
| Sponsored By:
|
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
Stock Market
Loading
